Issues in COVID-19 research and statistical analyses (Part XVVIII)
February 22, 2022 In a pre-print article published recently, the authors used life table and survival analyses methods to compare probability of dying from COVID-19 against probability of dying from other causes using data from the province Hubei of China, of which...
Issues in COVID-19 research and statistical analyses (Part XVVIII)
February 2, 2022 A recent article in the Lancet Infectious Diseases presents a large scale study of post-vaccination infection conducted in the United Kingdom to assess potential long-haul symptoms. It was a prospective, community-based, nested, case-control study...
Issues in COVID-19 research and statistical analyses (Part XVVII)
January 18, 2022 A recent article in the New England Journal of Medicine (NEJM) presents results from a large cohort study from New York State on COVID-19 vaccine effectiveness. They used data for 8,690,825 adults in New York State to assess the effectiveness of the...
Issues in COVID-19 research and statistical analyses (Part XVVI)
January 5, 2022 With the ongoing rise in COVID-19 cases due to the Omicron variant of Sars-Cov-2, we searched for some actual studies on the change in vaccine efficacy due to Omicron exposure. In one pre-print article, Buchan et al studied 3,442...
Issues in COVID-19 research and statistical analyses (Part XVV)
The new variant of COVID-19, Omicron, and boosters from vaccines has been receiving a lot of press. In an article published in BMJ on December 14, 2021, “Covid-19: Omicron and the need for boosters”, the authors take us through a detailed summary about how a booster...
Issues in COVID-19 research and statistical analyses (Part XVIV)
December 9, 2021 The new variant for Omicron is causing a lot of stir around the world. Most of the data analysis conducted thus far has been preliminary and other planned data analyses are taking weeks in order to understand the potential severity of the variant and...
Issues in COVID-19 research and statistical analyses (Part XVIII)
At home Antigen tests statistical results November 24, 2021 Antigen tests for SARS-CoV-2 are back and are pending more approvals by the current administration. If so, they may be used more often and more frequently to help people get back to a more normal lifestyle....
Issues in COVID-19 research and statistical analyses (Part XVII)
Pfizer anti-viral November 10, 2021 Pfizer, similar to Merck, has announced the efficacy of their anti-viral drug called PAXLOVID against SARS-CoV-2. The reported 89% efficacy against serious disease and 100% efficacy against death and they are making headlines....
Issues in COVID-19 research and statistical analyses (Part XVI)
Mix and match boosters October 27, 2021 In recent news, the CDC/FDA are approving booster shots not only for Pfizerã but also for Modernaã and Johnson & Johnsonã, and even mixing and matching these boosters, but is there any science behind this...
Issues in COVID-19 research and statistical analyses (Part XV)
Antivirals EUA October 13, 2021 In recent news, Merck and Ridgeback has been hailing an oral anti-viral drug against Sars-CoV-2 that can cut the hospitalization and death rates in half according to their news posted on Oct 1, 2021 on their website. Apparently, the...